Eli Lilly to Supply Bamlanivimab to Treat Covid-19 in Canada
By Stephen Nakrosis
Eli Lilly Canada said Tuesday it signed an agreement with the
Government of Canada to supply bamlanivimab to treat patients
suffering from Covid-19.
The company said it will supply an initial 26,000 doses between
December 2020 and February 2021 for US$32.5 million.
"Lilly is taking a data-driven approach to the worldwide
allocation of bamlanivimab according to our guiding principles that
prioritize countries according to their medical need," the company
said, adding "Additional doses will be supplied to Canada on a
monthly basis according to the medical need in Canada and the
availability of supply."
Lilly said bamlanivimab received authorization to treat certain
adult and pediatric patients 12 years of age or older with mild to
moderate Covid-19 on November 20.
--Write to Stephen Nakrosis at firstname.lastname@example.org
(END) Dow Jones Newswires
November 24, 2020 13:25 ET (18:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.